Condition
Neonatal Sepsis, Late-Onset
Total Trials
5
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Recruiting2
Completed1
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06772675Not ApplicableRecruiting
Vancomycin Reduction Practices (VRP) in the NICU
NCT07248761Phase 4Active Not Recruiting
Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial
NCT07152106Recruiting
Amniotic Fluid & the Preterm Gut
NCT05763680Unknown
Molecular Culture for the Diagnosis of Neonatal Sepsis
NCT04867135CompletedPrimary
Population Pharmacokinetics of Amikacin in Neonates
Showing all 5 trials